NRD
LXRX icon

Nebula Research & Development’s Lexicon Pharmaceuticals LXRX Stock Holding History

Nebula Research & Development’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-28,377
Closed -$65K – 583
2023
Q2 		$65K Buy
+28,377
New +$75.3K 0.05% 310

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Nebula Research & Development's LXRX Position: Q3 2023 in Review

Nebula Research & Development sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2023, closing a stake of 28,377 shares — an estimated $65K sold.

Nebula Research & Development first reported a position in LXRX in Q2 2023 and held it in 1 quarter. The position peaked at $65K in Q2 2023. 112 funds tracked by Wall St. Rank hold LXRX as of Q3 2023.

  • Nebula Research & Development reported no remaining Lexicon Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Nebula Research & Development sold 28,377 Lexicon Pharmaceuticals shares in Q3 2023, an estimated $65K.
  • Nebula Research & Development first reported a position in Lexicon Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Nebula Research & Development's Lexicon Pharmaceuticals position peaked at $65K in Q2 2023.
  • 112 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2023.

Based on Nebula Research & Development's 13F filing for Q3 2023, filed 14 Nov 2023.